COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica
J Neurol
.
2021 Dec;268(12):4479-4482.
doi: 10.1007/s00415-021-10578-7.
Epub 2021 Apr 27.
Authors
Ana Maria Cabal-Herrera
1
,
Farrah J Mateen
2
Affiliations
1
Department of Neurology, Massachusetts General Hospital, 165 Cambridge St., Office 627, Boston, MA, 02114, USA.
2
Department of Neurology, Massachusetts General Hospital, 165 Cambridge St., Office 627, Boston, MA, 02114, USA. fmateen@mgh.harvard.edu.
PMID:
33904965
PMCID:
PMC8076662
DOI:
10.1007/s00415-021-10578-7
No abstract available
Publication types
Case Reports
Letter
MeSH terms
Antibodies, Monoclonal, Humanized
Aquaporin 4
Autoantibodies
COVID-19* / diagnosis
Humans
Neuromyelitis Optica* / drug therapy
Substances
Antibodies, Monoclonal, Humanized
Aquaporin 4
Autoantibodies
eculizumab